Related Experiment Video

Updated: Mar 30, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.4K

The procurement landscape of pediatric tuberculosis treatment: a Global Drug Facility perspective

C Scott1, E Gardiner2, A de Lucia3

  • 1The Global Alliance for TB Drug Development, New York, New York, USA.

The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
|November 14, 2015
PubMed

Insights

New child-friendly tuberculosis (TB) drugs are available. Analysis of the Global Drug Facility

Area of Science:

  • Global Health
  • Pharmaceutical Policy
  • Infectious Diseases

Background:

  • Availability of child-friendly tuberculosis (TB) formulations is increasing.
  • Global initiatives by organizations like the TB Alliance and World Health Organization (WHO) aim to improve pediatric TB treatment access.
  • Understanding the market dynamics and distribution of pediatric TB drugs is crucial for effective delivery.

Purpose of the Study:

  • To characterize the market and distribution pathways for pediatric TB drugs.
  • To assess the functioning of the current market based on Global Drug Facility (GDF) data.
  • To identify lessons learned and opportunities for future pediatric TB medicine delivery.

Main Methods:

  • Analysis of Global Drug Facility (GDF) data on pediatric TB treatment delivery from 2007 to 2013.
  • Contextualization of GDF data with WHO estimates of pediatric TB burden.
  • Assessment of market functioning, lessons learned, and future opportunities.

Main Results:

  • The Global Drug Facility (GDF) is a major procurer and supplier of pediatric TB medications globally.
  • Between 2007 and 2013, GDF delivered over 580,000 pediatric TB treatments to more than 50 countries.
  • The data provides insights into the current market landscape and GDF's role in supplying quality pediatric TB drugs.

Conclusions:

  • The GDF plays a significant role in supplying pediatric TB treatments, particularly in high-burden countries.
  • Analysis of GDF's experience offers valuable lessons for improving the delivery of current and future pediatric TB medicines.
  • Further understanding of market dynamics is essential for optimizing pediatric TB drug access.

More Related Videos

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test08:10

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test

Published on: April 9, 2012

82.3K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.4K

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
864
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
373
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
699
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
704
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
462
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
330